Psychiatriki
October 8, 2024
Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis et al.
Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials...
Journal of Sleep Research
October 1, 2024
Courtney J Bolstad, Brigitte Holzinger, Serena Scarpelli et al.
The association between nightmare frequency (NMF) and suicidal ideation (SI) is well known, yet the impact of the COVID-19 pandemic on this relation is inconsistent. This study aimed to investigate changes in NMF, SI, and their association during the COVID-19 pandemic. Data were collected in 16 countries using a harmonised questionnaire. The sample included 9328 individuals (4848 women; age...
Journal of pediatric psychology
October 1, 2024
Molly Basch, Francesca Lupini, Sally Ho et al.
8 citations
To evaluate feasibility/acceptability of a virtual, group mindfulness-based intervention (MBI) adapted for pediatric type 1 diabetes (T1D). This two-way controlled trial randomized adolescents 1:1 to MBI (n = 20) or health education (HE; n = 22) groups lasting 6-7 weeks. Eligibility included 12-17 years, T1D ≥ 1 year, and elevated scores on PROMIS depression or anxiety measures. Recruitment,...
Contemporary Clinical Trials
October 1, 2024
Emily K. Johnson, Kathleen Ismond, Ashley Hyde et al.
3 citations
Symptoms of depression and anxiety are prevalent among adults with chronic health conditions, contributing to reduced quality of life, morbidity, and mortality. Mind-body wellness interventions (i.e. psychology programming, mindful movement, breathwork, meditation) may impact mental health symptoms, with online delivery offering access and scalability. Whether online mind-body wellness...
Australian & New Zealand Journal of Psychiatry
October 1, 2024
Zohaib Nadeem, Stephen Parker, Hugh McGovern et al.
19 citations
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses, the attitudes, knowledge and readiness of both mental health consumers and the general population remain largely unknown. A cross-sectional survey was conducted among Australians, targeting individuals with mental illness as potential mental health...
Journal of Psychopharmacology
September 20, 2024
Abigail E. Calder, Benjamin Rausch, Matthias E. Liechti et al.
17 citations
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this program represent a unique opportunity to analyze the real-world practice of PAT. Aims: This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers. For the patients,...
medRxiv Preprint Server
September 10, 2024
Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al.
4 citations
preprint
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine’s effects on...
The Medical Clinics of North America
September 1, 2024
Jesse Markman, Heidi Combs
5 citations
For more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors. There are newer medications, many with novel mechanisms of action, that have come to market; however, first-line treatments remain the same. There are now more robust data on the use of various...
Psychiatry research communications
September 1, 2024
Alexandra K Gold, Dustin J Rabideau, Daniel Nolte et al.
2 citations
Regardless of baseline psychiatric symptom severity, individuals can improve from psychotherapy, including from low-intensity psychosocial treatments. We conducted a secondary analysis of a randomized trial of low-intensity mindfulness interventions to explore if and how specific indices of baseline symptom severity were associated with well-being trajectories during treatment and follow-up. In...
Mindfulness
September 1, 2024
Diane Joss, Martin H. Teicher, Sara W. Lazar
11 citations
Mindfulness-based interventions (MBIs) have been shown to be beneficial for young adults with adverse childhood experiences (ACE), but the temporal course of the therapeutic effects is still not well understood. This study aimed to investigate MBI-induced weekly changes and long-term effects in trait mindfulness and psychological symptoms. This study analyzed longitudinal data from a...